Relay Therapeutics is a clinical-stage precision medicines company. Co. has deployed its technology platform to build a pipeline of product candidates to address targets in precision medicine where there is clear evidence linking target proteins to disease and where molecular diagnostics can identify relevant patients for treatment. Co. has initiated a clinical trial for one of its product candidates, RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced or metastatic FGFR2-altered solid tumors. The U.S. Food and Drug Administration has granted orphan drug designation to RLY-4008 for the treatment of cholangiocarcinoma. The RLAY stock yearly return is shown above.
The yearly return on the RLAY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RLAY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|